A woman treated with cyclophosphamide (Cytoxan, Neosar) may develop premature ovarian failure which affects fertility and can result in premature menopause.
Patient selection: woman with ovarian function receiving cyclophosphamide for cancer, autoimmune disorder or other condition.
Risk factors for premature ovarian failure:
(1) older age (> 40 years)
(2) higher cumulative cyclophosphamide dose
(3) certain drug-metabolizing polymorphisms
(4) other drugs or therapies affecting ovarian function
Protective factors:
(1) gonadotropin-releasing hormone agonists
To read more or access our algorithms and calculators, please log in or register.
